Effect of Proton Pump Inhibitors on Palpitations

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Palpitation is a common complaint. Patients frequently feel this symptom despite having normal rhythm during symptoms. I have seen many patients who improve significantly on treatment with proton pump inhibitors (PPI). It may be that gastritis provokes a feeling of discomfort that subsequently starts the feeling of palpitation. On searching literature I found no study that investigated the effect of PPI's on palpitations. Therefore I propose a study where the investigators randomize people with palpitations with normal heart rate (no arrhythmia) and no apparent cause such as anxiety or clear illness to receive either PPI or placebo. The result will help to investigate if the improvement is true and if the results are positive this can provide a simple treatment for a common problem.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jordan Collaborating Cardiology Group
• Treatments: Proton Pump Inhibitors; Rabeprazole

Criteria

Inclusion Criteria:

1. Persons with palpitations and no clear cause who are above the age of 16 years and who consent to the study will be included

2. Clear causes that should be excluded are true arrhythmia such SVT or VT or frequent premature atrial or ventricular contractions or any organic cause such as thyroid disorder, anemia (hg less than 11 g/dl) and obvious anxiety disorder

3. Arrhythmia can be excluded by an ECG showing sinus rhythm or sinus tachycardia during episodes or measurement of heart rate by a reliable method during symptoms showing regular heart rate less than 120 beats per minute.

4. Patient will be randomized to either PPI or placebo to be taken one table at night time

5. Patients will be provided with 2 weeks supply but will be evaluated at 10 days to see if symptoms improved

6. The two groups will be compared using statistical methods to see if there is difference in improvement.

Exclusion Criteria:

• Refusal to participate or sign consent form

• Frequency of symptoms less than 2 times per week

• Already taking PPI or H2 blocker